medRxiv 预印本· Ruiz Borrego, M., Cortes, J., Stradella, A., Bermejo, B., Escriva de Romani, S., Reboredo, C., Albacar, C., Garrigos, L., Kummel, S., Colleoni, M., Gebhart, G., Dalenc, F., Kerrou, K., Braga, S., Schmid, P., Marme, F., Di Cosimo, S., Notini, G., Martinez Garcia, E., Amaya-Garrido, A., Alcala Lopez, D., Mina, L., Rodriguez Morato, J., Tang, C., Biswas, D., Machura, B., Witowski, J., Geras, K. J., Park, J., Mancino, M., Perez Garcia, J. M., Llombart Cussac, A. ·· 1 天前精选AI 评分50
AI模型在PHERGain与PHERGain-2试验中预测HER2阳性早期乳腺癌病理缓解与预后
Multimodal Artificial Intelligence Predicts Pathological Response and Prognosis in HER2-Positive Early Breast Cancer Treated with Chemotherapy De-escalation Strategies: Analyses from PHERGain and PHERGain-2 Trials
AI 导读
medRxiv预印本报告，Ataraxis Breast平台的AI模型在PHERGain和PHERGain-2两项II期试验中评估对HER2阳性早期乳腺癌病理完全缓解（pCR）的预测能力。
推荐理由
PHERGain与PHERGain-2两项试验数据显示，AI模型评分与HER2阳性早期乳腺癌pCR及长期复发风险相关，为化疗降阶梯的患者筛选提供参考。
来源：medRxiv 预印本 · medrxiv.org